Cipher PharmaceuticalsCPHRF 96 Net Margin % is 49.28% as of Mar. 2026, which is 77% above its 10-year median of 27.83. GuruFocus rates CPHRF with a GF Score™ of 96/100 and a GF Value™ of $12.19 (Fairly Valued). The stock has 5 warning signs investors should review. Among 956 Drug Manufacturers companies, Cipher Pharmaceuticals ranks better than 98.22% on this metric.
The historical rank and industry rank for Cipher Pharmaceuticals's Net Margin % or its related term are showing as below:
CPHRF'
s Net Margin % Range Over the Past 10 Years
Min: -132.03 Med: 27.83 Max: 128.83
Current: 60.65
CPHRF's Net Margin % is ranked better than 98.22% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs CPHRF: 60.65
Cipher Pharmaceuticals (OTCPK:CPHRF) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Cipher Pharmaceuticals Net Margin % Related Terms
Cipher Pharmaceuticals Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cipher Pharmaceuticals's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cipher Pharmaceuticals Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cipher Pharmaceuticals's Net Margin % distribution charts can be found below:
* The bar in red indicates where Cipher Pharmaceuticals's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cipher Pharmaceuticals (CPHRF) has a Net Margin % of 49.28% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Cipher Pharmaceuticals and its competitors. This is 77% above median its historical median of 27.83. According to the industry distribution chart, Cipher Pharmaceuticals ranks #17 out of 956 companies in the Drug Manufacturers industry, placing it in the top 1.8%.
Is Cipher Pharmaceuticals' Net Margin % too high?
Cipher Pharmaceuticals' current Net Margin % of 49.28% is 77% above median its 10-year median of 27.83. The Drug Manufacturers industry median Net Margin % is 5.56. Cipher Pharmaceuticals' value of 49.28% is 786.3% above this industry median. Based on the distribution chart, Cipher Pharmaceuticals ranks #17 out of 956 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cipher Pharmaceuticals has a GF Score™ of 96/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cipher Pharmaceuticals' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cipher Pharmaceuticals ranks #17 out of 956 companies for Net Margin %. This places Cipher Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median Net Margin % is 5.56. Cipher Pharmaceuticals' value of 49.28% is 786.3% above this benchmark. While the company's 10-year median is 27.83 vs. the industry median of 5.56, Cipher Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cipher Pharmaceuticals's current Net Margin % of 49.28% is 786.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Cipher Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cipher Pharmaceuticals's current Net Margin % is 49.28%, which is 77% above median its own 10-year median of 27.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cipher Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Cipher Pharmaceuticals (CPHRF) is currently considered Fairly Valued. The stock's GF Value™ is $12.19, compared to a current price of $11.43 — trading 6.2% below its estimated fair value. The current Net Margin % is 49.28%, which is 77% above median its 10-year median of 27.83 and 786.3% above the Drug Manufacturers industry median of 5.56. Cipher Pharmaceuticals' overall GF Score™ is 96/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Cipher Pharmaceuticals (CPHRF), the current Net Margin % is 49.28% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cipher Pharmaceuticals (CPHRF) Overvalued in 2026?
Based on GuruFocus' analysis, Cipher Pharmaceuticals stock appears to be undervalued.
The current stock price of $11.43 is trading 6.2% below its estimated GF Value™ of $12.19.
GuruFocus considers Cipher Pharmaceuticals to be Fairly Valued.
Key valuation signals for CPHRF:
Net Margin %: 49.28% (77% above median its 10-year median of 27.83)
GF Value™: $12.19 vs. price of $11.43 (6.2% below fair value)
Industry Position: 786.3% above the Drug Manufacturers median (#17 of 956)
No single metric tells the full story. See the CPHRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cipher Pharmaceuticals Inc is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company is building its business through product acquisitions, out-licensing, and in-licensing arrangements. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products, among others. The company's geographical operational areas include Canada and the United States.
96GF Score
Get the complete analysis for CPHRF
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPHRF has been successfully added to your 
